Edwards Lifesciences Corp 4
4 · Edwards Lifesciences Corp · Filed Jul 31, 2012
Insider Transaction Report
Form 4
GARREN BRUCE P
CVP, Gov. Affairs/Gen. Counsel
Transactions
- Exercise/Conversion
Common Stock
2012-07-30$27.77/sh+21,000$583,170→ 83,748 total - Sale
Common Stock
2012-07-30$105.21/sh−500$52,605→ 93,248 total - Sale
Common Stock
2012-07-30$104.34/sh−30,500$3,182,370→ 62,748 total - Exercise/Conversion
Employee Stock Option (Right to Acquire)
2012-07-30−21,000→ 0 totalExercise: $27.77From: 2009-05-08Exp: 2015-05-07→ Common Stock (21,000 underlying) - Exercise/Conversion
Common Stock
2012-07-30$24.42/sh+10,000$244,200→ 93,748 total - Exercise/Conversion
Employee Stock Option (Right to Acquire)
2012-07-30−10,000→ 15,000 totalExercise: $24.42From: 2008-05-10Exp: 2014-05-09→ Common Stock (10,000 underlying)
Footnotes (4)
- [F1]This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator.
- [F2]This transaction was executed in multiple trades at prices ranging from $105.20 to $105.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $104.07 to $104.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.